Papers/PMID:35166140
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.
Journal of psychopharmacology (Oxford, England)2022The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
3,4-methylenedioxymethamphetamine — increases systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The MDMA group higher SBP and DBP compared to the placebo group.”
Quoted verbatim from A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.. - Study
- RCT
- Dose
- 100 mg single oral dose
- Population
- Healthy adults aged 21-55 with prior recreational MDMA use, single 100 mg oral dose versus matching placebo in a parallel-group trial; blood pressure monitored at eight timepoints over the 6 hours after dosing
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.2022PMID:35166140Industry fundedPermalink
3,4-methylenedioxymethamphetamine — increases diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The MDMA group higher SBP and DBP compared to the placebo group.”
Quoted verbatim from A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.. - Study
- RCT
- Dose
- 100 mg single oral dose
- Population
- Healthy adults aged 21-55 with prior recreational MDMA use, single 100 mg oral dose versus matching placebo in a parallel-group trial; blood pressure monitored at eight timepoints over the 6 hours after dosing
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.2022PMID:35166140Industry fundedPermalink